Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 60% of modeled bridge. Strengths: Bed Count. Risks: Occupancy Rate. Risk-adjusted uplift: $2.1M (vs $3.6M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $1.4M | $1.4M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $1.3M | $37K | $1.3M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $208K | $616K | $824K | $2.6M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $43K | $43K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 43.9% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $339K | $677K | $1.0M | $1.4M | $1.4M | $1.4M | $1.4M |
| Denial Rate Reduction | $0 | $335K | $670K | $1.0M | $1.3M | $1.3M | $1.3M | $1.3M |
| A/R Days Reduction | $0 | $275K | $549K | $824K | $824K | $824K | $824K | $824K |
| Clean Claim Rate | $0 | $22K | $43K | $43K | $43K | $43K | $43K | $43K |
| Cumulative | $0 | $970K | $1.9M | $2.9M | $3.6M | $3.6M | $3.6M | $3.6M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $3.6M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 159% / 116.8x | 165% / 130.2x | 170% / 143.5x | 172% / 150.2x | 175% / 156.9x |
| 9.0x | 153% / 103.5x | 158% / 115.4x | 164% / 127.2x | 166% / 133.2x | 168% / 139.1x |
| 10.0x | 147% / 92.8x | 153% / 103.5x | 158% / 114.2x | 160% / 119.5x | 163% / 124.8x |
| 11.0x | 143% / 84.1x | 148% / 93.8x | 153% / 103.5x | 155% / 108.3x | 158% / 113.2x |
| 12.0x | 138% / 76.8x | 144% / 85.7x | 148% / 94.6x | 151% / 99.0x | 153% / 103.5x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 92% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 0.5x, adding 7.9 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $233K | — | $233K | 0.3% |
| Year 1 | $240K | +$2.4M | $2.6M | 3.9% |
| Year 2 | $248K | +$3.6M | $3.8M | 5.6% |
| Year 3 | $255K | +$3.6M | $3.8M | 5.6% |
| Year 4 | $263K | +$3.6M | $3.8M | 5.6% |
| Year 5 | $271K | +$3.6M | $3.8M | 5.7% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $677K | $1.0M | $1.4M | $1.6M |
| Denial Rate Reductio | $670K | $1.0M | $1.3M | $1.6M |
| A/R Days Reduction | $412K | $618K | $824K | $989K |
| Clean Claim Rate | $22K | $32K | $43K | $52K |
| Total | $1.8M | $2.7M | $3.6M | $4.3M |
Peer Context — Where This Hospital Sits
Key metrics vs 73 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 0.3% | -12.4% | -3.5% | 7.2% | P58 |
| Net-to-Gross | 32.4% | 30.6% | 37.0% | 43.9% | P33 |
| Occupancy | 12.9% | 17.7% | 39.0% | 59.8% | P18 |
| Rev/Bed | $1.4M | $640K | $1.4M | $2.2M | P49 |
| Exp/Bed | $1.4M | $614K | $1.5M | $2.3M | P44 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.